Overview

Neuroimaging Studies of Dexmedetomidine- and Ketamine-Induced Analgesia

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Neuroimaging data will be collected for patients that are given low doses of dexmedetomidine and ketamine in order to understand their analgesic effects.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Dexmedetomidine
Ketamine